Mounjaro Outweighs Ozempic in Weight Loss: Study Finds
For those seeking the most effective weight loss drug, Mounjaro may be a better option than Ozempic. A recent study published in JAMA Internal Medicine on July 8 revealed that Mounjaro results in greater weight loss than Ozempic and Wegovy. The key ingredient in Mounjaro, tirzepatide, outperforms semaglutide, the active ingredient in Ozempic.
Over a year, patients on tirzepatide were more likely to achieve a 10% or higher weight loss, with some losing up to 15% of their body weight compared to 8% in those taking Ozempic or Wegovy. Check-ins at three, six, and twelve months consistently showed higher weight loss among tirzepatide users.
The study involved analyzing electronic health records of overweight or obese adults who began taking Mounjaro or Ozempic between May 2022 and September 2023. Most participants were white females with an average age of 52.
Dr. Sharon Giese from New York explains that Mounjaro acts on both GLP-1 and GIP receptors, making it more effective at enhancing insulin secretion and reducing appetite than semaglutide, which targets only GLP-1 receptors. Both drugs are highly effective, but Mounjaro appears to have the edge.
This information is not a substitute for professional medical advice or diagnosis. Always consult your physician before pursuing any treatment plan.
